VBValai Bussaratid

Valai Bussaratid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valai Bussaratid has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Boosbun Chua‐Intra

    Dermatology Section, Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health (MoPH), Nonthaburi, Thailand

    1 shared publication
  • Busaya Liebtawee

    1 shared publication
  • Jaranit Kaewkungwal

    Faculty of Tropical Medicine, Mahidol University, Thailand

    1 shared publication
  • Jirot Sindhvananda

    Institute of Dermatology, Department of Medical Services, MoPH, Bangkok, Thailand

    1 shared publication
  • Jittima Dhitavat

    Clinical Infectious Disease Research Unit, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

    1 shared publication
  • Kanokporn Jaisathaporn

    Division of Medical Oncology, National Cancer Institute, Department of Medical Services, MoPH, Bangkok, Thailand

    1 shared publication

Latest Publications

  • Measuring herpes zoster, zoster‐associated pain, post‐herpetic neuralgia‐associated loss of quality of life, and healthcare utilization and costs in Thailand

    by Kobkul Aunhachoke, Valai Bussaratid, Pornchai Chirachanakul, Boosbun Chua‐Intra, Jittima Dhitavat, Kanokporn Jaisathaporn, Jaranit Kaewkungwal, Kowit Kampirapap, Thiravud Khuhaprema, Kulprapat Pairayayutakul, et al.

    Objectives  This study aimed to measure the herpes zoster‐associated burden of illness, healthcare utilization, and costs among Thai patients.Methods  This prospective cohort study of 180 patients aged ≥ 50 years and healthy, or ≥ 20 years and immunosuppressed, with zoster rash, was conducted in Bangkok and its environs, Thailand, during 2007–2008. Each patient was followed for six months for zoster‐associated rash, pain, quality of life (QoL), and healthcare utilization and costs.Results  A total of 180 subjects were enrolled in the study. Their mean ± standard deviation (SD) age was 58.9 ± 13.8 years. Of the 180 patients enrolled, 138 (76.7%), 34 (18.9%) and eight (4.4%) patients were elderly, HIV‐infected, and receiving immunosuppressive agents, respectively; 35 (19.4%) had post‐herpetic neuralgia (PHN), and 13 (7.2%) had zoster ophthalmicus. The severity of zoster pain was moderately highly correlated with activities of daily living (ADL), at 0.68 ≤ ρ ≤ 0.76. Most patients required only one or two outpatient visits. The mean ± SD total of direct healthcare costs was 3083.4 ± 5047.0 Thai baht or ∼ 1.1% of annual income per capita.Conclusions  Herpes zoster contributes a significant burden of illness to both patients and the wider community.


    • 1 November 2010
      • Vol. 41  (6) , 1316-21

    Predictive factors for Gnathostoma seropositivity in patients visiting the Gnathostomiasis Clinic at the Hospital for Tropical Diseases, Thailand during 2000-2005.

    by Valai Bussaratid, Paron Dekumyoy, Varunee Desakorn, Naowarat Jaroensuk, Busaya Liebtawee, Wallop Pakdee, Yupaporn Wattanagoon

    This was a retrospective study of patients having Gnathostoma antibody testing at the Hospital for Tropical Diseases, Bangkok during 2000-2005 to investigate predictive factors for Gnathostoma seropositivity in patients attending the Gnathostomiasis Clinic. Out of 849 patients tested, 531 (62.5%) were Gnathostoma seropositive. The median absolute eosinophil counts were 464 (0-16,796) and 326.5 (0-10,971) cells/mm3 in seropositive and seronegative patients, respectively (p500 cells/mm3), and the frequency of cutaneous swellings between seropositive and seronegative patients were all statistically significant. Patients with a history of eating raw meat and a history of cutaneous swelling were at 2.1 and 1.8 times more likely to be Gnathostoma seropositive, respectively. Logistic regression analysis showed eosinophilia was not a predictive factor for Gnathostoma seropositivity.


    • 1 May 2005
      • Vol. 36  (3) , 644-9

    Tolerability of ivermectin in gnathostomiasis.

    by Valai Bussaratid, Srivicha Krudsood, Udomsak Silachamroon, Sornchai Looareesuwan

    At present, no universally-accepted effective treatment for cutaneous gnathostomiasis is available. At the Hospital for Tropical Diseases, Mahidol University, albendazole 400 mg twice a day for 14 days is commonly prescribed for patients diagnosed with cutaneous gnathostomiasis. The efficacy of albendazole to induce outward migration of the parasite was less than or around 20% in 2 studies. Research for alternative, more efficacious treatment, is needed. In this prospective open-labeled study, we assessed the safety of ivermectin in 20 Thai patients diagnosed with cutaneous gnathostomiasis. Ivermectin, one time only, at dosages of 50, 100, 150, or 200 microg/kg bodyweight, was given orally to 4 groups of patients, 5 patients each group. Adverse events were recorded and laboratory tests were obtained before and after treatment. No serious adverse events occurred in this study. Forty adverse events were possibly related to ivermectin. The adverse events were malaise (35%), myalgia (30%), drowsiness (30%), pruritus (20%), nausea/vomiting (20%), dizziness (15%), diarrhea (15%), feeling of shortness of breath (10%), feeling of palpitations (10%), constipation (5%), anorexia (5%), and headache (5%). These adverse events were self-limited and not dose-related. Laboratory abnormalities were found in 3 patients (15%). Transient microscopic hematuria, pyuria, and mildly elevated liver enzymes were found in 1 patient each. Ivermectin single dose, of 50,100, 150, and 200 microg/kg bodyweight, is considered safe in Thai patients. Future trials of ivermectin on human gnathostomiasis may be performed using dosages up to 200 microg/kg bodyweight.